TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 580285
Drug: Penfluridol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol, administered orally, once weekly
Study: 23748114
Drug: Fulranumab 6
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 6 mg every 8 weeks (Q8wk)
Study: 23748114
Drug: Fulranumab 3
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 3 mg every 4 weeks (Q4wk)
Study: 17227809
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (DG)
Study: 15287372
Drug: Dynamic exercise
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic exercise during euglycemic insulin clamp
Study: 15287372
Drug: Dynamic exercise
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic exercise during hyperglycemic insulin clamp
Study: 11706668
Drug: DEC 300
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 300 mg per day for 12 days
Study: 9152515
Drug: Selenized yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenized yeast tablet (200 micrograms daily for 4 years)
Study: 9152515
Drug: Placebo yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yeast tablet (identical to Se tablet)
Study: 9152515
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of Se treatment
Study: 9152515
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of Se treatment
Study: 8265093
Drug: EAP-1 (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAP-1 (doxorubicin 20 mg/m2 on days 1 and 7, cisplatin 40 mg/m2 on days 2 and 8, etoposide 120 mg/m2 on days 4-6)
Study: 31385178
Drug: Double-dose nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose nicorandil (30 mg/day)
Study: 31385178
Drug: Usual-dose nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose nicorandil (15 mg/day)
Study: 25875256
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily for 12 weeks
Study: 11496616
Drug: (S)-ketamine/propofol (0.33-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine/propofol (0.33-1.0 mg/kg BW/h (S)-ketamine + 1-3 mg/kg BW/h propofol)
Study: 30541492
Drug: Phase-based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-based Treatment (PBT; maximum of eight sessions skills training followed by eight sessions PE in 16 weeks)
Study: 26182736
Drug: Capsule Tamsulosin
Normalized name: tamsulosin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Tamsulosin 0.4 mg, 1 daily up to 4 weeks
Study: 26182736
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 Capsule daily up to 4 weeks
Study: 28984053
Drug: AS04-HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS04-HPV-16/18 vaccine
Study: 31315279
Drug: High-CGA coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CGA coffee (369 mg CGA/serving)
Study: 31315279
Drug: Control coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control coffee (35 mg CGA/serving)
Study: 28705592
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (bolus injection of 1.5 mg/kg at induction, continuous infusion of 2 mg/kg/h until end of surgery)
Study: 24158328
Drug: Microchip implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microchip implantation and control treatments
Study: 24856612
Drug: Twice-daily NPH
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily NPH
Study: 9677017
Drug: Elevated plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated plasma total homocysteine concentration (over 11.5 micromol/L)
Study: 9677017
Drug: Plasma total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma total homocysteine concentration below 11.5 micromol/L
Study: 18383657
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (not specified)
Study: 21797835
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (walking, light, and sleep education)
Study: 10614791
Drug: Alteplase or
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase or reteplase (thrombolysis treatment)
Study: 29921041
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of autologous platelet-rich plasma (PRP)
Study: 25239018
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain assessment using Pain Assessment in Advanced Dementia
Study: 25239018
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of average daily pain
Study: 17481879
Drug: Budesonide 1600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 mcg/day for 12 weeks
Study: 3771951
Drug: Standardized grass
Normalized name: DACTYLIS GLOMERATA POLLEN 5000 [BAU] in 1 mL / PHLEUM PRATENSE POLLEN 5000 [BAU] in 1 mL INTRADERMAL SOLUTION [Timothy-Orchard Standardized Grass Pollen Mix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized grass extract immunotherapy
Study: 28025967
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate tablet 50 mg (Jinge®, Test)
Study: 28025967
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate tablet 100 mg (Viagra®, Reference)
Study: 9848042
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) (approximately 10 micrograms/kg)
Study: 8011819
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate for 10 days plus alternate-day injections of interferon-gamma
Study: 29629828
Drug: Telephone-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioral therapy (T-CBT)
Study: 26086603
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading dose of Rosuvastatin before PCI (n = 264)
Study: 26086603
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 264)
Study: 16427545
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (100 mg/kg before skin incision followed by 1 g/hour continuous infusion until chest closure, 10 g in cardiopulmonary bypass circuit)
Study: 10971859
Drug: EPD (immunotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPD (immunotherapy)
Study: 8226141
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron radiation therapy
Study: 6439700
Drug: Conventional photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photon radiation therapy
Study: 28833748
Drug: Cognitive rehabilitation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation, cognitive behavioural therapy, and life review methods
Study: 21134123
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 650mg q4h
Study: 16780480
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% potassium hydroxide solution
Study: 14533336
Drug: Orthodontic Oral-B
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic Oral-B
Study: 14533336
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage 30
Study: 8649700
Drug: Weekly stripping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly stripping of membranes
Study: 8649700
Drug: Weekly gentle
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly gentle cervical examinations
Study: 1371197
Drug: Donor-specific transfusions
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-specific transfusions (DST) and continuous intravenous cyclosporine (CsA) initiated 24 hr before transplantation
Study: 30773542
Drug: 4 °C
Normalized name: The full generic name for the drug abbreviation '4 °C' is not clear from the information provided. The abbreviation '4 °C' typically refers to a temperature of 4 degrees Celsius, which is a common storage or incubation temperature used in various laboratory and clinical procedures, but it does not represent a specific drug or medication.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 °C RF‐APGD plasma jet treatment for 20 s
Study: 25730292
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal lidocaine
Study: 11560538
Drug: 15 mg/d
Normalized name: Valtoco, 15 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48 (n = 395)
Study: 19848198
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment only)
Study: 3382461
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cianopramine (acute administration)
Study: 3382461
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, and 3 mg cianopramine (chronic administration)
Study: 3382461
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg cianopramine (superimposed single dose after chronic administration)
Study: 10551706
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs)
Study: 23548855
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (440 mg of Mg oxide 3 times per week for 6 months)
Study: 21518840
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg efavirenz with 600 mg rifampin/day
Study: 8568310
Drug: US inactivated
Normalized name: Rabies virus inactivated antigen, A
DrugBank: Rabies virus inactivated antigen, A (DB10283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: US inactivated split-virus vaccine
Study: 25748698
Drug: hANP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP + DA (1-3 μg·kg·min)
Study: 25748698
Drug: hANP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP + furosemide (10-30 mg injection)
Study: 22737876
Drug: Compound betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound betamethasone injection 1 ml and benzathine penicillin 1 200 000 U, deeply injected into muscles on hips, one time.
Study: 22737876
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg orally once a day and amoxicillin capsules 0.5 mg orally three times a day, taken for one week.
Study: 17610528
Drug: TMC114/r (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/r (300/100 mg bid) plus TDF (300 mg qd)
Study: 17610528
Drug: TMC114/r (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/r (300/100 mg bid)
Study: 11937314
Drug: PVACE‐BOP therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVACE‐BOP therapy in the poorest risk group
Study: 10200005
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone at 1 mg/kg/dose (maximum 60 mg/dose) four times daily
Study: 1825568
Drug: GR32191 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 (80 mg po and 40 mg po)
Study: 29199012
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of CLS‐TA
Study: 25244776
Drug: Yupingfeng droppill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yupingfeng droppill and cetirizine tablets
Study: 25244776
Drug: Cetirizine tablets
Normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine tablets
Study: 21877203
Drug: Tenofovir 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 1% gel (CT cohort)
Study: 12209372
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (yoghurt enriched with L. acidophilus 145, B. longum 913 and 1% oligofructose)
Study: 10023014
Drug: subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous epoetin á 150 U/kg three times a week for up to 12 consecutive weeks (Group A)
Study: 10023014
Drug: subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous epoetin á 50 U/kg daily for up to 12 consecutive weeks (Group B)
Study: 2676173
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release isosorbide-5-mononitrate (ISM) 60 mg
Study: 2857210
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg twice a day
Study: 25720388
Drug: Intravenous exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous exenatide
Study: 11304934
Drug: Doxepin-ratiopharm 25
Normalized name: doxepin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin-ratiopharm 25 mg film-coated tablets (test preparation)
Study: 6539187
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine
Study: 3552464
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg albuterol (Salbutamol)
Study: 29346473
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in primary care
Study: 24116853
Drug: Adjunctive brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brivaracetam (BRV) 20-150 mg/day
Study: 18587525
Drug: Cu-(II)-orotate-dihydrate; 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cu-(II)-orotate-dihydrate; 8 mg Cu daily
Study: 11874243
Drug: Nasal SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal SCT (200 IU daily)
Study: 2346342
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of atropine
Study: 19252346
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/day) + Sibutramine (10 mg/day)
Study: 19252346
Drug: Metformin (3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3,000 mg/day) + Sibutramine (10 mg/day)
Study: 16298763
Drug: Enzogenol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol (480 mg) and vitamin C (60 mg)
Study: 16298763
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (60 mg) alone
Study: 8431330
Drug: Midazolam 3-10
Normalized name: midazolam 14.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3-10 mg
Study: 3583405
Drug: Desipramine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (specific inhibitor of neuronal uptake)
Study: 3583405
Drug: Hydrocortisone (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (highest dose without neuronal uptake inhibition)
Study: 28709817
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatment with daily oral antihistamine
Study: 28709817
Drug: Second line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line treatment with higher dose antihistamine
Study: 28709817
Drug: Third line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third line treatment with omalizumab or cyclosporine
Study: 28777519
Drug: Surgical intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical intervention without HBO₂ therapy (Group 1)
Study: 7532763
Drug: Anipamil 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anipamil 80 mg once daily
Study: 7532763
Drug: Anipamil 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anipamil 160 mg once daily
Study: 2442550
Drug: Lisinopril (LIS)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (LIS) 20, 40, and 80 mg
Study: 2442550
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5, 25, and 50 mg
Study: 2442550
Drug: Lisinopril +
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril + Hydrochlorothiazide (LIS + HCTZ) 20 + 12.5, 40 + 25, and 80 + 50 mg
Study: 31822399
Drug: Selinexor (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (35 or 50 mg/m2 twice‐weekly [BIW] or 50 mg/m2 once‐weekly [QW])
Study: 31822399
Drug: Selinexor (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (50 mg/m2 QW)
Study: 30768411
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for anxiety
Study: 29603219
Drug: Child-centered therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-centered therapy (CCT)
Study: 28238674
Drug: Participatory Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory Action Research (PAR) weekly sessions
Study: 28238674
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (weekly reminiscence activity)
Study: 23615633
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with telmisartan (80 mg/d) and aliskiren (300 mg/d)
Study: 23615633
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with telmisartan (160 mg/d) alone
Study: 23615633
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with telmisartan (80 mg/d) and eplerenone (50 mg/d)
Study: 21840177
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (twice daily for 14 days)
Study: 17070365
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tadalafil
Study: 17125930
Drug: l-Arg (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Arg (400 mg/kg/day)
Study: 17125930
Drug: l-Arg (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Arg (200 mg/kg/day)
Study: 17125930
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no l-Arg supplementation)
Study: 11444449
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.5 mL
Study: 11435054
Drug: Gallamine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.04 mg/kg
Study: 7878625
Drug: Hirulog 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 1.0 mg/kg subcutaneously
Study: 7878625
Drug: Hirulog 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.6 mg/kg as a 15 min intravenous infusion
Study: 3067338
Drug: Olsalazine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine, 2 g/day
Study: 29786964
Drug: Laquinimod 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.6 mg/day
Study: 17043157
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg per day)
Study: 10397122
Drug: Negative contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative contrast agent (30 patients)
Study: 28580810
Drug: Youth Empowerment
Normalized name: influenza A virus A/South Australia/34/2019 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth Empowerment Solutions (YES) program
Study: 30352746
Drug: Homeopathic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic vaccine
Study: 20453154
Drug: Aerobic treadmill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic treadmill exercise (T-EX) therapy
Study: 1967425
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: 6751339
Drug: Bromocriptine (30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (30-50 mg daily)
Study: 6751339
Drug: Amitriptyline (120-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (120-200 mg daily)
Study: 15220226
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day Alendronate (ALN) for 2 years, followed by 10 mg/day for the remainder of the trial
Study: 17000586
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone therapy (1 mg estradiol plus 0.5 mg norethisterone)
Study: 30938806
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (NC) diet with 1.3 g nPP/kg starter diet or 1.1 g nPP/kg grower diet